A ressonância magnética cardíaca (RMC) é uma técnica sem radiação, considerada padrão para avaliação da anatomia, função e até composição do tecido cardíaco. O estudo RESILIENCE usará a RMC como a principal metodologia para medir os resultados da intervenção e os doentes inscritos no estudo serão submetidos a três exames ao longo da duração do estudo.
Ensaio clínico multinacional, prospectivo, de prova de conceito, de fase II com dupla ocultação, controlado com simulação, aleatorizado (RCT) para avaliar a eficácia e segurança do Condicionamento Isquémico Remoto (RIC) em doentes com linfoma não Hodgkin (LNH) que são tratados com antraciclinas. Os doentes programados para receberem pelo menos 5 ciclos de quimioterapia com antraciclinas são elegíveis para participar no estudo.
When a new medical intervention begins to be tested in people, research progresses through different phases of clinical trials. Each phase is designed to answer specific questions and provide more information about the intervention’s safety, potential effectiveness, and how it should be investigated further. Phase II plays a particularly important
Overcoming cancer marks the beginning of a new chapter. However, some effects of the disease and its treatments may persist or appear long after treatment has ended. Among these are hormonal changes, which in some individuals, may also have implications for cardiovascular health. These changes depend on several factors, including
How research is changing the way we protect the hearts of people with cancer. In recent years, cardio-oncology has evolved from an emerging discipline into a key area of cancer patient care. As cancer survival rates continue to improve, preventing, detecting, and treating the cardiovascular complications associated with certain cancer
Beating Cancer Is the Beginning of a New Chapter Advances in oncology have enabled more people than ever before to survive cancer and enjoy longer lives after treatment. However, completing cancer treatment does not always mark the end of medical follow-up. For many patients, it represents the beginning of a
Protecting the heart during cancer treatment Advances in oncology have significantly improved survival rates for people with cancer. However, some cancer therapies can affect cardiovascular health, a phenomenon known as cardiotoxicity. This potential impact on the heart has become one of the main challenges in cardio-oncology, a field focused on
Advances in oncology have made it possible for more and more people to overcome cancer. However, some cancer treatments can have effects on the cardiovascular system, making heart protection a key part of care during and after treatment. This connection between cancer and the heart is the focus of cardio-oncology,
